Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome
Open Access
- 25 April 2020
- journal article
- editorial
- Published by Elsevier BV in Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale
- Vol. 158 (1), e15-e19
- https://doi.org/10.1016/j.chest.2020.04.024
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- SARS-CoV-2: a storm is ragingJCI Insight, 2020
- Tocilizumab treatment in COVID‐19: A single center experienceJournal of Medical Virology, 2020
- Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortalityInternational Journal of Antimicrobial Agents, 2020
- Clinical and virological data of the first cases of COVID-19 in Europe: a case seriesThe Lancet Infectious Diseases, 2020
- Clinical and immunological features of severe and moderate coronavirus disease 2019JCI Insight, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2018
- Cytokine release syndromeJournal for ImmunoTherapy of Cancer, 2018